98 related articles for article (PubMed ID: 3115927)
1. Transforming growth factor activity in pleural and peritoneal effusions from cancer and non-cancer patients.
Sairenji M; Suzuki K; Murakami K; Motohashi H; Okamoto T; Umeda M
Jpn J Cancer Res; 1987 Aug; 78(8):814-8. PubMed ID: 3115927
[TBL] [Abstract][Full Text] [Related]
2. Immunoreactive alpha transforming growth factor activity in effusions from cancer patients as a marker of tumor burden and patient prognosis.
Arteaga CL; Hanauske AR; Clark GM; Osborne CK; Hazarika P; Pardue RL; Tio F; Von Hoff DD
Cancer Res; 1988 Sep; 48(17):5023-8. PubMed ID: 3165707
[TBL] [Abstract][Full Text] [Related]
3. Positive effusion cytology as the initial presentation of malignancy.
Monte SA; Ehya H; Lang WR
Acta Cytol; 1987; 31(4):448-52. PubMed ID: 3604540
[TBL] [Abstract][Full Text] [Related]
4. [Expression of transforming growth factor beta-3 (TGF-beta-3) on reactive and malignant cells in ascites and pleural effusion].
Munker R; Darsow M; Stötzer O; Kremer JP; Mezger J
Med Klin (Munich); 1994 May; 89(5):248-51. PubMed ID: 8052178
[TBL] [Abstract][Full Text] [Related]
5. The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions.
Sears D; Hajdu SI
Acta Cytol; 1987; 31(2):85-97. PubMed ID: 3469856
[TBL] [Abstract][Full Text] [Related]
6. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease.
Kraft A; Weindel K; Ochs A; Marth C; Zmija J; Schumacher P; Unger C; Marmé D; Gastl G
Cancer; 1999 Jan; 85(1):178-87. PubMed ID: 9921991
[TBL] [Abstract][Full Text] [Related]
8. Soluble aminopeptidase N/CD13 in malignant and nonmalignant effusions and intratumoral fluid.
van Hensbergen Y; Broxterman HJ; Hanemaaijer R; Jorna AS; van Lent NA; Verheul HM; Pinedo HM; Hoekman K
Clin Cancer Res; 2002 Dec; 8(12):3747-54. PubMed ID: 12473585
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions.
Duysinx BC; Corhay JL; Hubin L; Nguyen D; Henket M; Louis R
Respir Med; 2008 Dec; 102(12):1708-14. PubMed ID: 18760578
[TBL] [Abstract][Full Text] [Related]
10. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.
Yeo KT; Wang HH; Nagy JA; Sioussat TM; Ledbetter SR; Hoogewerf AJ; Zhou Y; Masse EM; Senger DR; Dvorak HF
Cancer Res; 1993 Jun; 53(12):2912-8. PubMed ID: 8504432
[TBL] [Abstract][Full Text] [Related]
11. The metabolic behaviour of the cellular populations in the pleural or peritoneal effusions from patients with malignant diseases.
Mihăilescu E; Micu D; Cheţa N; Chiriloiu C; Georgescu M; Vilău C
Med Interne; 1986; 24(3):227-33. PubMed ID: 2430328
[TBL] [Abstract][Full Text] [Related]
12. The interval between the diagnosis of malignancy and the development of effusions, with reference to the role of cytologic diagnosis.
van de Molengraft FJ; Vooijs GP
Acta Cytol; 1988; 32(2):183-7. PubMed ID: 3348059
[TBL] [Abstract][Full Text] [Related]
13. High level of beta-type transforming growth factor activity in human urine obtained from cancer patients.
Nishimura R; Okumura H; Noda K; Yasumitsu H; Umeda M
Jpn J Cancer Res; 1986 Jun; 77(6):560-7. PubMed ID: 3089989
[TBL] [Abstract][Full Text] [Related]
14. Cytomorphological and immunocytochemical study of non-Hodgkin's lymphoma in pleural effusion and ascitic fluid.
Das DK; Al-Juwaiser A; George SS; Francis IM; Sathar SS; Sheikh ZA; Shaheen A; Pathan SK; Haji BE; George J; Kapila K
Cytopathology; 2007 Jun; 18(3):157-67. PubMed ID: 17488258
[TBL] [Abstract][Full Text] [Related]
15. Distinct high-performance liquid chromatography pattern of transforming growth factor activity in urine of cancer patients as compared with that of normal individuals.
Kimball ES; Bohn WH; Cockley KD; Warren TC; Sherwin SA
Cancer Res; 1984 Aug; 44(8):3613-9. PubMed ID: 6331653
[TBL] [Abstract][Full Text] [Related]
16. Determination of transforming growth factor activity in effusions from cancer patients.
Hanauske AR; Arteaga CL; Clark GM; Buchok J; Marshall M; Hazarika P; Pardue RL; Von Hoff DD
Cancer; 1988 May; 61(9):1832-7. PubMed ID: 3162700
[TBL] [Abstract][Full Text] [Related]
17. An immunoperoxidase study of S-100 protein in neoplastic cells in serous effusions. Use as a marker for melanoma.
Pinto MM
Acta Cytol; 1986; 30(3):240-4. PubMed ID: 3521174
[TBL] [Abstract][Full Text] [Related]
18. Tumor microenvironment: what can effusions teach us?
Kassis J; Klominek J; Kohn EC
Diagn Cytopathol; 2005 Nov; 33(5):316-9. PubMed ID: 16240401
[TBL] [Abstract][Full Text] [Related]
19. [Ascites and pleural effusion. Study and follow-up of 79 patients].
Molina M; Ortega G; Vidal L; Montoya JJ; Pérez A; García B
Rev Esp Enferm Apar Dig; 1989 Oct; 76(4):375-8. PubMed ID: 2595069
[TBL] [Abstract][Full Text] [Related]
20. Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy.
Gieseler F; Lühr I; Kunze T; Mundhenke C; Maass N; Erhart T; Denker M; Beckmann D; Tiemann M; Schulte C; Dohrmann P; Cavaillé F; Godeau F; Gespach C
Thromb Haemost; 2007 Jun; 97(6):1023-30. PubMed ID: 17549306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
